CytomX Therapeutics to Report Third Quarter 2024 Financial Results on November 7, 2024
CytomX Therapeutics to Report Third Quarter 2024 Financial Results on November 7, 2024
SOUTH SAN FRANCISCO, Calif., Oct. 31, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologic therapeutics, today announced that it will report third quarter financial results on Thursday, November 7, 2024, after the close of U.S. markets. Following the announcement, the Company will host a conference call and webcast at 5:00 p.m. ET / 2:00 p.m. PT.
位於加利福尼亞州南舊金山，2024年10月31日（環球新聞社）--cytomx therapeutics，inc. （納斯達克：ctmx）是掩體條件激活生物製品治療領域的領軍者，今天宣佈將於2024年11月7日星期四在美國市場收盤後公佈第三季度財務業績。在公告後，公司將於東部時間下午5:00 / 太平洋時間下午2:00召開電話會議和網絡直播。
Participants may access the live webcast of the conference call from the Events and Presentations page of CytomX's website at . An archived replay of the webcast will be available on the Company's website.
參與者可以從cytomx網站的事件和演示頁面訪問電話會議的現場網絡直播。電話會議的存檔重播將在公司網站上提供。
Audio Conference Call:
電話會議：
| U.S. Dial-in Number: | (800) 715-9871 | ||
| International Dial-in Number: | (646) 307-1963 | ||
| Conference ID: | 5171678 |
| 美國撥入號碼： | (800) 715-9871 | ||
| 國際撥打電話號碼： | (646) 307-1963 | ||
| 會議ID： | 5171678 |
About CytomX Therapeutics, Inc.
CytomX is a clinical-stage, oncology-focused biopharmaceutical company focused on developing novel conditionally activated biologics designed to be localized to the tumor microenvironment. By pioneering a novel pipeline of localized biologics, powered by its PROBODY therapeutic platform, CytomX's vision is to create safer, more effective therapies for the treatment of cancer. CytomX's robust and differentiated pipeline comprises therapeutic candidates across multiple treatment modalities including antibody-drug conjugates ("ADCs"), T-cell engagers, and immune modulators such as cytokines. CytomX's clinical-stage pipeline includes CX-904, CX-2051 and CX-801. CX-904 is a conditionally activated T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells. CX-904 is partnered with Amgen in a global co-development alliance. CX-2051 is a conditionally activated ADC directed toward epithelial cell adhesion molecule, EpCAM, with potential applicability across multiple EpCAM-expressing epithelial cancers. CX-2051 was discovered in collaboration with Immunogen, now part of AbbVie. CX-801 is an interferon alpha-2b PROBODY cytokine with broad potential applicability in traditionally immuno-oncology sensitive as well as insensitive (cold) tumors. CytomX has established strategic collaborations with multiple leaders in oncology, including Amgen, Astellas, Bristol Myers Squibb, Regeneron and Moderna. For more information about CytomX and how it is working to make conditionally activated treatments the new standard-of-care in the fight against cancer, visit and follow us on LinkedIn and X (formerly Twitter).
關於CytomX Therapeutics公司
CytomX是一家致力於開發新型條件激活生物製品的臨床前期腫瘤專注生物製藥公司，旨在將其PROBODY治療平台帶動的專一化的生物製品創新流水線推廣到腫瘤微環境，以創造更安全、更有效的癌症治療方案。CytomX豐富和差異化的流水線跨越多種治療模式，包括抗體藥物複合物(「ADC」)，細胞激活劑和細胞因子等免疫調節劑。CytomX的臨床流水線包括CX-904、CX-2051和CX-801。CX-904是一種條件激活的t細胞激活雙特異性抗體，靶向腫瘤細胞上的表皮生長因子受體(EGFR)和t細胞上的CD3受體。CX-904在全球合作開發聯盟中與Amgen合作。CX-2051是一種條件激活的抗體藥物複合物，用於對抗多種表達上皮細胞粘附分子(EpCAm)的上皮癌症。CX-2051是與Immunogen合作發現的，Immunogen現在是AbbVie的一部分。CX-801是一種廣泛應用於傳統免疫腫瘤學敏感和不敏感(cold)腫瘤的干擾素α-20億PROBODY細胞因子。CytomX已與多個腫瘤領域的領軍企業，包括Amgen、愛J突利、BMS、Regeneron和moderna等建立了戰略合作伙伴關係。欲了解CytomX的更多信息以及如何在與癌症的鬥爭中，使條件激活治療成爲新的標準，請訪問並關注LinkedIn和X(以前的Twitter)。
Company Contact:
Chris Ogden
Chief Financial Officer
cogden@cytomx.com
公司聯繫人：
克里斯•奧格登
首席財務官
cogden@cytomx.com
Investor Contact:
Precision AQ (formerly Stern Investor Relations)
Stephanie Ascher
stephanie.ascher@precisionaq.com
投資者聯繫人：
Precision AQ（前斯特恩投資者關係）
斯蒂芬妮•阿舍
stephanie.ascher@precisionaq.com
Media Contact:
Redhouse Communications
Teri Dahlman
teri@redhousecomms.com
媒體聯繫人：
Redhouse Communications
特里•達爾曼
teri@redhousecomms.com
譯文內容由第三人軟體翻譯。
